中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 35 Issue 10
Oct.  2019
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(10): 2150-2155

Serum HBsAg quantification in clinical diagnosis and treatment of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2019.10.004

  • Research Laboratory of Clinical Virology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine

Research funding:

 

  • Received Date: 2019-07-29
  • Published Date: 2019-10-20
    Abstract
  • HBsAg is one of the oldest diagnostic markers for HBV infection,and serum HBsAg level is associated with HBV cccDNA level in hepatocytes,HBV replication capability,and host immune response. In recent years,with the development of serum HBsAg quantification and the concept of functional cure,HBsAg quantification has been taken more and more seriously in the clinical diagnosis and treatment of HBV infection. This article analyzes the role of serum HBsAg quantification from the aspects of natural disease course of chronic hepatitis B,prediction of response to antiviral therapy,and prediction of drug withdrawal.

     

    • FullText(HTML)
    • References(40)
  • [1] CORNBERG M,WONG VW,LOCARNINI S,et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol,2017,66(2):398-411.
    [2] COFFIN CS,ZHOU K,TERRAULT NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection[J]. Gastroenterology,2019,156(2):355-368. e3.
    [3] LIU J,YANG HI,LEE MH,et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression[J]. Hepatology,2016,64(2):381-389.
    [4] YU DM,LI XH,MOM V,et al. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape[J]. J Hepatol,2014,60(3):515-522.
    [5] WARNER N,LOCARNINI S. The antiviral drug selected hepatitis B virus rt A181T/s W172*mutant has a dominant negative secretion defect and alters the typical profile of viral rebound[J]. Hepatology,2008,48(1):88-98.
    [6] CHAN HL,WONG VW,TSE AM,et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol,2007,5(12):1462-1468.
    [7] CHAN HL,WONG VW,WONG GL,et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology,2010,52(4):1232-1241.
    [8] NGUYEN T,THOMPSON AJ,BOWDEN S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:A perspective on Asia[J]. J Hepatol,2010,52(4):508-513.
    [9] THOMPSON AJ,NGUYEN T,ISER D,et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers:Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers[J]. Hepatology,2010,51(6):1933-1944.
    [10] FATTOVICH G,OLIVARI N,PASINO M,et al. Long-term outcome of chronic hepatitis B in Caucasian patients:Mortality after 25 years[J]. Gut,2008,57(1):84-90.
    [11] BROUWER WP,CHAN HL,BRUNETTO MR,et al. Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up[J]. Clin Gastroenterol Hepatol,2016,14(10):1481-1489. e5.
    [12] BRUNETTO MR,OLIVERI F,COLOMBATTO P,et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers[J]. Gastroenterology,2010,139(2):483-490.
    [13] SALI S,SHARAFI H,ALAVIAN SH,et al. Can serum level of HBsAg differentiate HBe Ag-negative chronic hepatitis B from inactive carrier state?[J]. Diagn Microbiol Infect Dis,2015,82(2):114-119.
    [14] World Health Organization. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[R].Geneva:WHO,2015.
    [15] SETO WK,WONG DK,FUNG J,et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B[J]. PLo S One,2012,7(8):e43087.
    [16] MARTINOT-PEIGNOUX M,CARVALHO-FILHO R,LAPALUS M,et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-nave,e antigenpositive patients[J]. J Hepatol,2013,58(6):1089-1095
    [17] MARCELLIN P,MARTINOT-PEIGNOUX M,ASSELAH T,et al. Serum levels of hepatitis B surface antigen predict severity of fibrosis in patients with e antigen-positive chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2015,13(8):1532-1539. e1.
    [18] LIANG LB,ZHU X,YAN LB,et al. Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBe Ag-positive chronic hepatitis B patients[J]. Ther Clin Risk Manag,2015,11:229-235.
    [19] XUN YH,ZANG GQ,GUO JC,et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers[J]. J Gastroenterol Hepatol,2013,28(11):1746-1755.
    [20] JANSSEN HL,KERHOF-LOS CJ,HEIJTINK RA,et al. Measurement of HBs Ag to monitor hepatitis B viral replication in patients on alpha-interferon therapy[J]. Antiviral Res,1994,23(3-4):251-257.
    [21] MARTINOT-PEIGNOUX M,ASSELAH T,MARCELLIN P. HBs Ag quantification to optimize treatment monitoring in chronic hepatitis B patients[J]. Liver Int,2015,35(Suppl 1):82-90.
    [22] SONNEVELD MJ,HANSEN BE,PIRATVISUTH T,et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J]. Hepatology,2013,58(3):872-880.
    [23] MOUCARI R,MACKIEWICZ V,LADA O,et al. Early serum HBs Ag drop:A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBe Ag-negative patients[J].Hepatology,2009,49(4):1151-1157.
    [24] MARCELLIN P,BONINO F,YURDAYDIN C,et al. Hepatitis B surface antigen levels:Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int,2013,7(1):88-97.
    [25] PAVLOVIC V,YANG L,CHAN HL,et al. Peginterferon alfa-2a(40 kD)stopping rules in chronic hepatitis B:A systematic review and meta-analysis of individual participant data[J].Antivir Ther,2019,24(2):133-140.
    [26] CHEVALIEZ S,HZODE C,BAHRAMI S,et al. Long-term hepatitis B surface antigen(HBs Ag)kinetics during nucleoside/nucleotide analogue therapy:Finite treatment duration unlikely[J]. J Hepatol,2013,58(4):676-683.
    [27] KIM WR,BERG T,ASSELAH T,et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol,2016,64(4):773-780.
    [28] WURSTHORN K,JUNG M,RIVA A,et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients[J]. Hepatology,2010,52(5):1611-1620.
    [29] HEATHCOTE EJ,MARCELLIN P,BUTI M,et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology,2011,140(1):132-143.
    [30] ZOUTENDIJK R,ZAAIJER HL,de VRIES-SLUIJS TE,et al.Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV[J]. J Infect Dis,2012,206(6):974-980.
    [31] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B:Results from a nineyear longitudinal study[J]. J Gastroenterol,2013,48(8):930-941.
    [32] SETO WK,WONG DK,FUNG J,et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy[J]. Hepatology,2013,58(3):923-931.
    [33] HADZIYANNIS E,LARAS A. Viral biomarkers in chronic HBe Ag negative HBV infection[J]. Genes(Basel),2018,9(10). pii:E469.
    [34] BROQUETAS T,GARCIA-RETORTILLO M,HERNANDEZ JJ,et al. Quantification of HBs Ag to predict low levels and seroclearance in HBe Ag-negative patients receiving nucleos(t)ide analogues[J]. PLo S One,2017,12(11):e0188303.
    [35] GRAMENZI A,LOGGI E,MICCO L,et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients[J]. J Viral Hepat,2011,18(10):e468-e474.
    [36] SU CW,WU CY,HUNG HH,et al. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy[J]. J Gastroenterol Hepatol,2013,28(12):1849-1858.
    [37] TERRAULT NA,LOK ASF,McMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
    [38] SARIN SK,KUMAR M,LAU GK. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015 update[J]. Hepatol Int,2016,10(1):1-98.
    [39] QIU YW,HUANG LH,YANG WL,et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J]. Int J Infect Dis,2016,43:43-48.
    [40] WANG CC,TSENG KC,HSIEH TY,et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J]. Am J Gastroenterol,2016,111(9):1286-1294.
    • Relative Articles

  • Relative Articles

    [1]Huimin LI, Yizhuo CHEN, Rui ZHAO, Xiao HUANG, Fei HUANG, Huanhuan LI. A comparative analysis of the hemogram and myelogram of patients with liver cirrhosis and the advantages and disadvantages of splenectomy[J]. Journal of Clinical Hepatology, 2023, 39(9): 2217-2224. doi: 10.3969/j.issn.1001-5256.2023.09.028
    [2]Yitong BAI, Lianjie LIN, Dongmei PEI. Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(4): 805-809. doi: 10.3969/j.issn.1001-5256.2022.04.013
    [3]Mou SiYu, Yang Zhe, Wu LiQun, Qiu Xuan, Guo JiaMing. Predictive factors for portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 106-111. doi: 10.3969/j.issn.1001-5256.2018.01.022
    [4]Ao Fei, Chen WeiQing. Research advances in portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(3): 631-634. doi: 10.3969/j.issn.1001-5256.2018.03.043
    [5]Bao WenChun, Qi XingShun, Tang ShanHong, Li HongYu. An excerpt of the Japanese research group on IPH: diagnosis and treatment guidelines for aberrant portal hemodynamics (2017)[J]. Journal of Clinical Hepatology, 2017, 33(3): 432-434. doi: 10.3969/j.issn.1001-5256.2017.03.006
    [6]Liu ShuYan. Association between cerebral hemodynamic changes and neonatal hyperbilirubinemia[J]. Journal of Clinical Hepatology, 2017, 33(10): 1974-1976. doi: 10.3969/j.issn.1001-5256.2017.10.025
    [7]Tang HanQiu. Clinical effect of laparoscopic splenectomy combined with esophagogastric devascularization in treatment of liver cirrhosis with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(9): 1743-1746. doi: 10.3969/j.issn.1001-5256.2016.09.022
    [8]Liang XiaoHua, Zhang Feng, Zhu GeYuZheng. Effect of transjugular intrahepatic portosystemic shunt combined with splenic artery embolization on hepatic hemodynamics and liver function in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2112-2117. doi: 10.3969/j.issn.1001-5256.2016.11.021
    [9]Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization  the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
    [10]Yang ZhengMao, Zhang LingYi. Risk factors for portal vein thrombosis following splenectomy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1173-1175. doi: 10.3969/j.issn.1001-5256.2015.07.044
    [11]Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
    [12]Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012
    [14]Jin HongHui, Ding XiaoHong. ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(6): 456-458.
    [15]Gao Lei, Jing Xiang, Zhao XinMin, Zuo YanLing. Hemodynamics of portal vein in cirrhotic patients with esophageal varices[J]. Journal of Clinical Hepatology, 2010, 26(3): 297-299+305.
    [16]Liu SuLi, Feng ZhiJie, Lu: YanChun, Niu FaLiang. The clinical study of Rhizoma alismatis on hemodynamics of liver cirrohosis and portal hypertension[J]. Journal of Clinical Hepatology, 2006, 22(2): 119-120.
    [17]Qin YouJuan. Correlative study between hemodynamics of portal vein system and Child-Pugh in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 21-22.
    [18]Wang ZhiHua, Cai HanZhi, Zhao AnXin, Li XiLing, Yang HongXin. The effects of disconnection and shunt procedure on hepatic hemodynamics and function of active cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2002, 18(5): 309-310.
    [19]Dong JiLiang, Sun Jie, Ding XiuHe. Clinical observation of the effects of partial splenic embobization (PSE) on hemodynamics in 24 patients of liver cirrhosis with portal hypertention (LCPH)[J]. Journal of Clinical Hepatology, 2002, 18(6): 361-362.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(5)

    1. 康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 .
    2. 许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 .
    3. 彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 .
    4. 李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 .
    5. 黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.9 %FULLTEXT: 4.9 %META: 87.2 %META: 87.2 %PDF: 7.9 %PDF: 7.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.5 %其他: 4.5 %其他: 0.4 %其他: 0.4 %Arlington: 0.1 %Arlington: 0.1 %China: 0.6 %China: 0.6 %India: 0.1 %India: 0.1 %Taichung: 0.4 %Taichung: 0.4 %[]: 0.1 %[]: 0.1 %三明: 0.1 %三明: 0.1 %上海: 8.7 %上海: 8.7 %东京都: 0.1 %东京都: 0.1 %东莞: 0.4 %东莞: 0.4 %乌鲁木齐: 0.4 %乌鲁木齐: 0.4 %佛山: 0.1 %佛山: 0.1 %保定: 0.1 %保定: 0.1 %北京: 10.7 %北京: 10.7 %南京: 1.2 %南京: 1.2 %南宁: 0.4 %南宁: 0.4 %南昌: 0.2 %南昌: 0.2 %厦门: 0.2 %厦门: 0.2 %合肥: 0.2 %合肥: 0.2 %吉林: 0.5 %吉林: 0.5 %哥伦布: 0.1 %哥伦布: 0.1 %唐山: 0.5 %唐山: 0.5 %四平: 0.2 %四平: 0.2 %多伦多: 0.1 %多伦多: 0.1 %大连: 0.5 %大连: 0.5 %天津: 1.2 %天津: 1.2 %安康: 0.2 %安康: 0.2 %官坑: 0.1 %官坑: 0.1 %广州: 0.2 %广州: 0.2 %张家口: 1.1 %张家口: 1.1 %德阳: 0.1 %德阳: 0.1 %意法半: 0.2 %意法半: 0.2 %成都: 0.9 %成都: 0.9 %新加坡: 0.1 %新加坡: 0.1 %无锡: 0.2 %无锡: 0.2 %昆明: 1.0 %昆明: 1.0 %杭州: 0.9 %杭州: 0.9 %格兰特县: 0.1 %格兰特县: 0.1 %森尼韦尔: 0.1 %森尼韦尔: 0.1 %武汉: 1.0 %武汉: 1.0 %沈阳: 0.4 %沈阳: 0.4 %沧州: 0.1 %沧州: 0.1 %洛阳: 0.7 %洛阳: 0.7 %海口: 0.1 %海口: 0.1 %深圳: 0.6 %深圳: 0.6 %渭南: 0.1 %渭南: 0.1 %湛江: 0.4 %湛江: 0.4 %石家庄: 0.4 %石家庄: 0.4 %福州: 0.2 %福州: 0.2 %秦皇岛: 0.1 %秦皇岛: 0.1 %芒廷维尤: 25.6 %芒廷维尤: 25.6 %芝加哥: 0.4 %芝加哥: 0.4 %苏州: 0.4 %苏州: 0.4 %莫斯科: 0.6 %莫斯科: 0.6 %西宁: 15.1 %西宁: 15.1 %西安: 0.2 %西安: 0.2 %诺沃克: 0.1 %诺沃克: 0.1 %郑州: 0.1 %郑州: 0.1 %重庆: 0.5 %重庆: 0.5 %锦州: 0.1 %锦州: 0.1 %长春: 0.2 %长春: 0.2 %长沙: 10.7 %长沙: 10.7 %长治: 0.1 %长治: 0.1 %青岛: 3.8 %青岛: 3.8 %其他其他ArlingtonChinaIndiaTaichung[]三明上海东京都东莞乌鲁木齐佛山保定北京南京南宁南昌厦门合肥吉林哥伦布唐山四平多伦多大连天津安康官坑广州张家口德阳意法半成都新加坡无锡昆明杭州格兰特县森尼韦尔武汉沈阳沧州洛阳海口深圳渭南湛江石家庄福州秦皇岛芒廷维尤芝加哥苏州莫斯科西宁西安诺沃克郑州重庆锦州长春长沙长治青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1790) PDF downloads(479) Cited by(5)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1352]YesterdayPV[2703]TodayIP[1573]TodayPV[2687]Online[56]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return